Abstract

Compositions for enhancing TFEB-mediated intracellular clearance are herein. Particularly, a complex comprising synergistic combination of polyamine and histidine-containing dipeptide present in a specific weight ratio along with pharmaceutically acceptable excipients is provided herein. More particularly, the composition comprises a synergistic blend of N-(3-Aminopropyl)-1,4-butanediamine and N-α-Acetyl-N-β-alanyl-L-histidine and salts thereof along with pharmaceutically acceptable excipients. Furthermore, the present synergistic composition is useful for improving or inducing autophagy, lysosomal biogenesis, mitophagy and lipophagy.

IPC Classes  ?

• A61K 38/05 - Dipeptides
• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention disclosed herein relates to synergistic composition for improving HPG axis activity. Particularly, the present invention relates to a synergistic bioactive composition comprising combination of 2-aminobutanedioic acid and one or more ROS inhibitors or salts thereof along with pharmaceutically acceptable excipients. The present composition is useful in in the treatment of disorders related to hypothalamic pituitary gonadal (HPG) axis activity such as male infertility. Particularly, the present composition improves sperm mortality, sperm capacitation, sperm morphology and spermatogenesis.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

(MTHFR)(MTHFR) regulators and salts thereof, present in suitable weight ratio along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 475/00 - Heterocyclic compounds containing pteridine ring systems
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention disclosed herein relates to synergistic composition for modulating expression of cyclic ADP ribose hydrolase (CD38). Particularly, the present invention relates to synergistic bioactive composition comprising therapeutic blend of bioactive sesquiterpenoid and at least one potent glucose uptake promoters present in specific weigh percentage along with pharmaceutically acceptable excipients. The present synergistic composition is useful in improving intracellular signaling activity, particularly the composition is used for treating upregulated cyclic ADP ribose hydrolase (CD38) disorders.

IPC Classes  ?

• A61K 31/365 - Lactones
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present invention relates to a synergistic composition for enhancing activity of PINK1/PARKIN pathway. Particularly, the present invention relates to synergistic bioactive composition comprising combination of benzo-coumarin compound and at least one cell viability enhancer along with pharmaceutically acceptable excipients. The composition is useful in the treatment of obesity, diabetes, cancer, liver diseases, sexual dysfunction, neurodegenerative diseases, cardiovascular diseases, osteoarthritis, musculoskeletal diseases, neuromuscular diseases, and kidney diseases.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 31/37 - Coumarins, e.g. psoralen
• C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
• C07D 311/80 - DibenzopyransHydrogenated dibenzopyrans

Abstract

The invention disclosed herein related to an oral, algal oil-based, gastro-intestinal tract permeable peptide composition. Particularly, the invention relates to the oral, water in algal oil-based, peptide compositions for the treatment of glucose metabolic disorders comprising peptides that generally degraded in GIT, a protease inhibitor and algal oil enriched with stabilized DHA along with pharmaceutically acceptable excipients, wherein protease inhibitor forms stoichiometric complex with the protease active site with activity of 5000 to 10,000 BAEE units per mg protein.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 38/22 - Hormones
• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61K 38/55 - Protease inhibitors
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention disclosed herein relates to synergistic bioactive compositions for inhibiting vascular calcification. Particularly, the present invention relates to exogenous blend of magnesium 2-acetylamino ethane sulfonic acid and 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol and salts thereof which are present in the weight ratio of 1:0.002 to 1:1.8 along with pharmaceutically acceptable excipients. More particularly, the synergistic composition is useful for treating cardiovascular diseases and renal vascular diseases.

IPC Classes  ?

• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids

Abstract

The invention disclosed herein relates to synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases. Particularly, the invention relates to synergistic nutritional compositions comprising an exogenous blend of N-acetyl-DL-leucine (NADLL) enantiomerically enriched with L-leucine and uridine monophosphate (UMP) which are present in a weight ratio of 1:0.002 to 1:0.8 along with pharmaceutically acceptable excipients. The composition of the present invention is useful for treating dizziness, imbalance, vertigo, tinnitus, hearing loss, brain fog, vision impairment, cognitive changes, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), motor neurone disease (MND), multiple system atrophy (MSA), and Parkinson's disease (PD).

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to compositions for enhancing TFEB-mediated intracellular clearance. Particularly, the invention relates to complex comprising synergistic combination of polyamine and histidine-containing dipeptide present in a specific weight ratio along with pharmaceutically acceptable excipients. More particularly, the invention relates to composition comprising synergistic blend of N-(3-Aminopropyl)-1,4-butanediamine and N-α-Acetyl-N-β-alanyl-L-histidine and salts thereof along with pharmaceutically acceptable excipients. Furthermore, the present synergistic composition is useful for improving or inducing autophagy, lysosomal biogenesis, mitophagy and lipophagy.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention discloses herein related to synergistic combination of exogenous bioactives for activating intracellular secondary messenger (cAMP) signalling pathway. Particularly, the invention relates to synergistic compositions comprising combination of therapeutically effective amount of (3R)-3-acetyloxy-4-(trimethylazaniumyl) butanoate and N-4-aminobutylguanidine and salts thereof present in a weight ratio of 1:0.01 to 1:2 along with pharmaceutically acceptable excipients. Furthermore, the composition is useful for treating disease conditions or disorders related to depletion of secondary messenger pathway. The present invention further provides method of treating disease conditions related mental illness or disorder.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/075 - Ethers or acetals
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl-3-N-Butylphthalide (NBP) and SIRT1 activators, wherein D1-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/13 - Nucleic acids or derivatives thereof
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention disclosed herein related to an oral, algal oil-based, gastro-intestinal tract permeable peptide composition. Particularly, the invention relates to the oral, water in algal oil- based, peptide compositions for the treatment of glucose metabolic disorders comprising peptides that generally degraded in GIT, a protease inhibitor and algal oil enriched with stabilized DHA along with pharmaceutically acceptable excipients, wherein protease inhibitor forms stoichiometric complex with the protease active site with activity of 5000 to 10,000 BAEE units per mg protein.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 38/22 - Hormones
• A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention disclosed herein relates to synergistic bioactive compositions for inhibiting vascular calcification. Particularly, the present invention relates to exogenous blend of magnesium 2-acetylamino ethane sulfonic acid and 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol and salts thereof which are present in the weight ratio of 1:0.002 to 1:1.8 along with pharmaceutically acceptable excipients. More particularly, the synergistic composition is useful for treating cardiovascular diseases and renal vascular diseases.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07D 213/66 - One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulfur, or nitrogen atom, e.g. pyridoxal

Abstract

The present invention disclosed herein relates to a synergistic composition for potentiating stabilized ATP. Particularly, the invention provides the synergistic composition for improving cellular energy in a subject in need thereof. More particularly, the invention relates to compositions comprising synergistic combination therapeutically active ALCAR and MgAT which are present in the weight ratio of 1:0.002 to 1:1, along with pharmaceutically acceptable excipients, Further, the present composition is useful for improving tiredness, fatigue, cognition, memory, increase mental alertness, concentration, endurance, boost energy levels and wakefulness. It also useful for treating depression, anxiety related symptoms.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A23L 33/175 - Amino acids

Abstract

The present invention disclosed herein relates to a synergistic composition for potentiating stabilized ATP. Particularly, the invention provides the synergistic composition for improving cellular energy in a subject in need thereof. More particularly, the invention relates to compositions comprising synergistic combination therapeutically active ALCAR and MgAT which are present in the weight ratio of 1:0.002 to 1:1, along with pharmaceutically acceptable excipients. Further, the present composition is useful for improving tiredness, fatigue, cognition, memory, increase mental alertness, concentration, endurance, boost energy levels and wakefulness. It also useful for treating depression, anxiety related symptoms.

IPC Classes  ?

• A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The invention discloses herein related to synergistic combination of exogenous bioactives for activating intracellular secondary messenger (cAMP) signalling pathway. Particularly, the invention relates to synergistic compositions comprising combination of therapeutically effective amount of (3R)-3-acetyloxy-4-(trimethylazaniumyl) butanoate and N-4-aminobutylguanidine and salts thereof present in a weight ratio of 1:0.01 to 1:2 along with pharmaceutically acceptable excipients. Furthermore, the composition is useful for treating disease conditions or disorders related to depletion of secondary messenger pathway. The present invention further provides method of treating disease conditions related mental illness or disorder.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention disclosed herein relates to synergistic bioactive compositions for treating neurological disorders. Particularly, the invention relates to anti-ischemic nutritional compositions. More particular, the invention relates to synergistic, efficient, nutritional compositions for treating cerebral ischemia comprising therapeutically active exogenous combination of a decarboxylated L-arginine called agmatine (AGM) and a bio-optimized palmitoylethanolamide (Bio-PEA) and salts thereof, wherein the decarboxylated L-arginine salt i.e., agmatine sulfate and bio-optimized palmitoylethanolamide (PEA) are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention disclosed herein is related to novel synergistic nutritional compositions for treating neurocognitive disorders. Particularly, the invention provides a stable nutritional composition for treating neurocognitive disorders comprising an exogenous blend of magnesium L-threonate and homotaurine present in the weight ratio of 1:0.1 to 1:1, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating neurocognitive disorders such as Alzheimer's disease (AD), dementia, and Attention-deficit/hyperactivity disorder.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention disclosed herein related to novel synergistic nutritional compositions for treating neurocognitive disorders. Particularly, the invention provides stable nutritional composition for treating neurocognitive disorders comprising exogenous blend of magnesium L-threonate and homotaurine present in the weight ratio of 1:0.1 to 1:1, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating neurocognitive disorders such as Alzheimer's disease (AD); dementia; Attention-deficit/hyperactivity disorder and like thereof.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention disclosed herein relates to synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases. Particularly, the invention relates to synergistic nutritional compositions comprising an exogenous blend of N-acetyl-DL-leucine (NADLL) enantiomerically enriched with L-leucine and uridine monophosphate (UMP) which are present in a weight ratio of 1:0.002 to 1:0.8 along with pharmaceutically acceptable excipients. The composition of the present invention is useful for treating dizziness, imbalance, vertigo, tinnitus, hearing loss, brain fog, vision impairment, cognitive changes, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), motor neurone disease (MND), multiple system atrophy (MSA), and Parkinson's disease (PD).

IPC Classes  ?

• A23L 33/175 - Amino acids
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to synergistic bioactive compositions for enhancing cellular energy in aerobic or anaerobic conditions. Particularly, the invention relates to a synergistic bioactive composition comprising specific combination of purine nucleoside and hydrophilic pyridinecarboxamide compound(s) which are present in the ratio of 1:0.1 to 1:1 along with pharmaceutically acceptable carriers/excipients, wherein ‘purine nucleoside’ is inosine adduct and the hydrophilic pyridinecarboxamide compound is selected from nicotinamide riboside or nicotinamide mononucleotide either alone or in combination thereof. Further, the present cellular energy enhancing bioactive compositions are useful for treating ATP deficiency conditions. Moreover, the composition is useful for treating hepatic dysfunctions.

IPC Classes  ?

• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Goods & Services

Arranging and conducting online workshops in the field of wellness; Educational and entertainment services, namely, providing motivational speaking services in the field of self and personal improvement; Physical fitness training services; Provision of educational courses relating to diet Conducting of psychological assessments and examinations; Counseling in the field of mental health and wellness; Counseling services in the fields of health, nutrition and lifestyle wellness; Mental health screening services; Providing information in the field of psychological counseling and treatment; Providing information in the field of mental health and wellness via a website

Abstract

+/2+Bz) as d-amino acid oxidase enzyme (DAAO) inhibitor, which are present in weight ratio of 1:0.001 to 1:1.5 along with pharmaceutically acceptable excipients. Further the present synergistic medicinal composition is useful for treating certain neuropsychiatric disorders, neurological disorders and metabolic disorders.

IPC Classes  ?

• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The invention disclosed herein relates to a novel synergistic nutritional composition for promoting axonal regeneration. Particularly, the present invention provides potent nutritional composition comprising synergistic exogenous blend of agmatine (decarboxylated L-arginine) and inosine monophosphate (IMP) and salts thereof, which are present in a weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. The instant synergistic nutritional composition is useful for treating diseases or disorders related to traumatic injury in the central nervous system such as brain or spinal cord injury, optic nerve lesions.

IPC Classes  ?

• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention disclosed herein relates to a novel synergistic nutritional composition for promoting axonal regeneration. Particularly, the present invention provides potent nutritional composition comprising synergistic exogenous blend of agmatine (decarboxylated L-arginine) and inosine monophosphate (IMP) and salts thereof, which are present in a weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. The instant synergistic nutritional composition is useful for treating diseases or disorders related to traumatic injury in the central nervous system such as brain or spinal cord injury, optic nerve lesions.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention disclosed herein relates to novel synergistic medicinal compositions for treating dysfunctional D-serine (DSR) signaling. Particularly the invention provides potent synergistic medicinal composition comprising combination of N-acetyl taurinate salt of divalent metal (M2+AT) as serine racemase enzyme (SR) activator/stimulator and benzoic acid ester salt of monovalent or divalent metals (M+/2+Bz) as d-amino acid oxidase enzyme (DAAO) inhibitor, which are present in weight ratio of 1:0.001 to 1:1.5 along with pharmaceutically acceptable excipients. Further the present synergistic medicinal composition is useful for treating certain neuropsychiatric disorders, neurological disorders and metabolic disorders.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The invention disclosed herein relates to novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases. Particularly, the invention relates to potent and stable synergistic nutritional composition comprising combination of therapeutically active non-competitive amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR) antagonists and nuclear factor erythroid 2-related factor 2 (NRF2) activators, present in weight ratio of 1:0.001 to 1:0.5, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating conditions associated with seizure, fibrosis and diabetes.

IPC Classes  ?

• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention disclosed herein relates to novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases. Particularly, the invention relates to potent and stable synergistic nutritional composition comprising combination of therapeutically active non-competitive amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR) antagonists and nuclear factor erythroid 2-related factor 2 (NRF2) activators, present in weight ratio of 1:0.001 to 1:0.5, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating conditions associated with seizure, fibrosis and diabetes.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

IPC Classes  ?

• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 33/32 - ManganeseCompounds thereof
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof

Abstract

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

IPC Classes  ?

• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid

Goods & Services

Biological preparations for use in industry and science; Chemicals for use in industry and science; Unprocessed artificial resins Dietary supplements for human beings and animals; Dietetic foods adapted for medical use; Food for babies; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders Online advertising and marketing services in the field of mental wellness and mental healthcare

Abstract

The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl-3-N-Butylphthalide (NBP) and SIRT1 activators, wherein Dl-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention disclosed herein provides synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction. Particularly, the invention relates to synergistic, efficient, nutritional composition for comprising specific combination of decarboxylated L-arginine called agmatine sulphate and nicotinamide riboside chloride, wherein agmatine sulphate and nicotinamide riboside chloride are present in the weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. More particularly, the present invention offers synergistic effect for ameliorating neural dysfunction encompasses cerebrovascular diseases, neurodevelopmental disorders, mood disorders, mental health disorders and like thereof.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A23L 33/175 - Amino acids
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)

Abstract

The present invention disclosed herein provides synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction. Particularly, the invention relates to synergistic, efficient, nutritional composition for comprising specific combination of decarboxylated L-arginine called agmatine sulphate and nicotinamide riboside chloride, wherein agmatine sulphate and nicotinamide riboside chloride are present in the weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. More particularly, the present invention offers synergistic effect for ameliorating neural dysfunction encompasses cerebrovascular diseases, neurodevelopmental disorders, mood disorders, mental health disorders and like thereof.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants

Abstract

The present invention disclosed herein relates to synergistic bioactive compositions for treating neurological disorders. Particularly, the invention relates to anti-ischemic nutritional compositions. More particular, the invention relates to synergistic, efficient, nutritional compositions for treating cerebral ischemia comprising therapeutically active exogenous combination of a decarboxylated L-arginine called agmatine (AGM) and a bio-optimized palmitoylethanolamide (Bio-PEA) and salts thereof, wherein the decarboxylated L-arginine salt i.e., agmatine sulfate and bio-optimized palmitoylethanolamide (PEA) are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention disclosed herein relates to synergistic lipid controlling compositions. Particularly it relates to synergistic, non-statin medicinal compositions of therapeutically active substances for lipid profile management. More particularly, the present invention provides synergistic lipid controlling composition comprising inclusion complex of bempedoic acid (BA) with 'cyclodextrin' (CD); optionally in presence of disaccharide bioenhancer called 'trehalose' along with pharmaceutically acceptable carriers. The present synergistic non-statin medicinal composition is useful for treating or controlling hyperlipidemia, hypercholesterolemia, atherosclerosis, myocardial infarction and like thereof, with improved bioavailability.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

The present invention relates to synergistic bioactive compositions for enhancing cellular energy in aerobic or anaerobic conditions. Particularly, the invention relates to a synergistic bioactive composition comprising specific combination of purine nucleoside and hydrophilic pyridinecarboxamide compound(s) which are present in the ratio of 1:0.1 to 1:1 along with pharmaceutically acceptable carriers / excipients, wherein 'purine nucleoside' is inosine adduct and the hydrophilic pyridinecarboxamide compound is selected from nicotinamide riboside or nicotinamide mononucleotide either alone or in combination thereof. Further, the present cellular energy enhancing bioactive compositions are useful for treating ATP deficiency conditions. Moreover, the composition is useful for treating hepatic dysfunctions.

IPC Classes  ?

• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1:0.1 to 1:1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.

IPC Classes  ?

• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The present invention discloses herein a synergistic composition(s) of bioactive agents for optimizing cellular health. Particularly, a synergistic bioactive composition for optimizing cellular health, wherein the composition comprising therapeutic blend of betaine of thiol histidine and sirtuin activator(s) or salts thereof present in the ratio of 1:0.5 to 1:90, along with pharmaceutically acceptable excipients. In another embodiment, the invention discloses novel synergistic nutritional composition comprising synergistic combination of bioactives L-ergothioneine and nicotinamide mononucleotide chloride present in the ratio ranges from 1:1 to 1:80. The present invention provides promising and effective nutritional composition for improving cellular health by regulating expression of transcriptional factor, pro-inflammatory cytokines, and reducing cell apoptosis, ROS level and DNA damage in the cell.

IPC Classes  ?

• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A23L 33/175 - Amino acids
• A23L 33/15 - Vitamins
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine

Abstract

The present invention herein discloses potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function. Particularly, the invention relates to synergistic nutritional composition comprising exogenous blend of N1-methyl nicotinamide chloride and standardized red spinach extract enriched with nitrate content along with pharmaceutically acceptable excipients, wherein N1-methyl nicotinamide salt and standardized red spinach extract enriched with nitrate content are present in the ratio of 1: 0.5 to 1: 8; and N1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1: 0.1 to 1: 1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.

IPC Classes  ?

• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention discloses a synergistic nutritional composition(s) for pain management. Particularly, the invention relates to synergistic nutritional composition comprising specific combination of palmitoylethanolamide (PEA) and standardized red spinach extract enriched with nitrate content, present in the ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable carriers /excipients. More particularly the invention discloses synergistic nutritional composition comprising combination of PEA and nitrate of the red spinach extract, which are present in the ratio of 1: 0.01 to 1: 0.5. Further the instant synergistic composition is useful for treating neuropathic pain, particularly in the treatment of subject suffering with diabetic peripheral neuropathy and/or small fiber neuropathy.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present invention herein discloses novel synergistic composition comprising SIRT1 and AMPK activators for treating metabolic syndrome. Particularly the composition comprising therapeutic blend of SIRT1 activator(s) and stabilized AMPK activator(s) present in the ratio of 1: 1 to 1: 5, along with pharmaceutically acceptable excipients. More particularly the invention discloses novel synergistic nutritional composition comprising synergistic combination of N1-methylnicotinamide salt to oxaloacetic acid to standardized ascorbic acid present in the ratio ranges from 1:1:1 to 1:2:2, more particularly 1: 1.1: 1.6. The present synergistic nutritional compositions are useful for treating a subject suffering from metabolic syndrome such as hypertension, obesity, hyperlipidemia and diabetes and other related cardiovascular diseases. Further it improves ATP level and antioxidant activity.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention discloses herein a synergistic composition(s) of bioactive agents for optimizing cellular health. Particularly, a synergistic bioactive composition for optimizing cellular health, wherein the composition comprising therapeutic blend of betaine of thiol histidine and sirtuin activator(s) or salts thereof present in the ratio of 1: 0.5 to 1: 90, along with pharmaceutically acceptable excipients. In another embodiment, the invention discloses novel synergistic nutritional composition comprising synergistic combination of bioactives L-ergothioneine and nicotinamide mononucleotide chloride present in the ratio ranges from 1:1 to 1: 80. The present invention provides promising and effective nutritional composition for improving cellular health by regulating expression of transcriptional factor, pro-inflammatory cytokines, and reducing cell apoptosis, ROS level and DNA damage in the cell.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/06 - Antiabortive agentsLabour repressants
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention discloses a synergistic nutritional composition(s) for pain management. Particularly, the invention relates to synergistic nutritional composition comprising specific combination of palmitoylethanolamide (PEA) and standardized red spinach extract enriched with nitrate content, present in the ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable carriers/excipients. More particularly the invention discloses synergistic nutritional composition comprising combination of PEA and nitrate of the red spinach extract, which are present in the ratio of 1:0.01 to 1:0.5. Further the instant synergistic composition is useful for treating neuropathic pain, particularly in the treatment of subject suffering with diabetic peripheral neuropathy and/or small fiber neuropathy.

IPC Classes  ?

• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides

Abstract

The present invention discloses a synergistic nutritional composition(s) for pain management. Particularly, the invention relates to synergistic nutritional composition comprising specific combination of palmitoylethanolamide (PEA) and standardized red spinach extract enriched with nitrate content, present in the ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable carriers /excipients. More particularly the invention discloses synergistic nutritional composition comprising combination of PEA and nitrate of the red spinach extract, which are present in the ratio of 1: 0.01 to 1: 0.5. Further the instant synergistic composition is useful for treating neuropathic pain, particularly in the treatment of subject suffering with diabetic peripheral neuropathy and/or small fiber neuropathy.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The present invention herein discloses potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function. Particularly, the invention relates to synergistic nutritional composition comprising exogenous blend of N1-methyl nicotinamide chloride and standardized red spinach extract enriched with nitrate content along with pharmaceutically acceptable excipients, wherein N1-methyl nicotinamide salt and standardized red spinach extract enriched with nitrate content are present in the ratio of 1: 0.5 to 1: 8; and N1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1: 0.1 to 1: 1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.

IPC Classes  ?

• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention disclosed herein provides synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction. Particularly, the invention relates to synergistic, efficient, nutritional composition for comprising specific combination of decarboxylated L-arginine called agmatine sulphate and nicotinamide riboside chloride, wherein agmatine sulphate and nicotinamide riboside chloride are present in the weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. More particularly, the present invention offers synergistic effect for ameliorating neural dysfunction encompasses cerebrovascular diseases, neurodevelopmental disorders, mood disorders, mental health disorders and like thereof.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants

Abstract

The invention disclosed herein relates to synergistic bioactive compositions for inhibiting vascular calcification. Particularly, the present invention relates to exogenous blend of magnesium 2-acetylamino ethane sulfonic acid and 2-methyl-4-aminomethyl-5-hydroxymethyl-3-pyridinol and salts thereof which are present in the weight ratio of 1:0.002 to 1:1.8 along with pharmaceutically acceptable excipients. More particularly, the synergistic composition is useful for treating cardiovascular diseases and renal vascular diseases.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07D 213/66 - One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulfur, or nitrogen atom, e.g. pyridoxal

Abstract

The invention discloses herein related to synergistic combination of exogenous bioactives for activating intracellular secondary messenger (cAMP) signalling pathway. Particularly, the invention relates to synergistic compositions comprising combination of therapeutically effective amount of (3R)-3-acetyloxy-4-(trimethylazaniumyl) butanoate and N-4-aminobutylguanidine and salts thereof present in a weight ratio of 1:0.01 to 1:2 along with pharmaceutically acceptable excipients. Furthermore, the composition is useful for treating disease conditions or disorders related to depletion of secondary messenger pathway. The present invention further provides method of treating disease conditions related mental illness or disorder.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/075 - Ethers or acetals
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention disclosed herein relates to a novel synergistic nutritional composition for promoting axonal regeneration. Particularly, the present invention provides potent nutritional composition comprising synergistic exogenous blend of agmatine (decarboxylated L-arginine) and inosine monophosphate (IMP) and salts thereof, which are present in a weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. The instant synergistic nutritional composition is useful for treating diseases or disorders related to traumatic injury in the central nervous system such as brain or spinal cord injury, optic nerve lesions.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/708 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention disclosed herein relates to synergistic bioactive compositions for treating neurological disorders. Particularly, the invention relates to anti-ischemic nutritional compositions. More particular, the invention relates to synergistic, efficient, nutritional compositions for treating cerebral ischemia comprising therapeutically active exogenous combination of a decarboxylated L-arginine called agmatine (AGM) and a bio-optimized palmitoylethanolamide (Bio-PEA) and salts thereof, wherein the decarboxylated L-arginine salt i.e., agmatine sulfate and bio-optimized palmitoylethanolamide (PEA) are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention discloses herein a synergistic composition(s) of bioactive agents for optimizing cellular health. Particularly, a synergistic bioactive composition for optimizing cellular health, wherein the composition comprising therapeutic blend of betaine of thiol histidine and sirtuin activator(s) or salts thereof present in the ratio of 1: 0.5 to 1: 90, along with pharmaceutically acceptable excipients. In another embodiment, the invention discloses novel synergistic nutritional composition comprising synergistic combination of bioactives L-ergothioneine and nicotinamide mononucleotide chloride present in the ratio ranges from 1:1 to 1: 80. The present invention provides promising and effective nutritional composition for improving cellular health by regulating expression of transcriptional factor, pro-inflammatory cytokines, and reducing cell apoptosis, ROS level and DNA damage in the cell.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/06 - Antiabortive agentsLabour repressants
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl-3-N-Butylphthalide (NBP) and SIRT1 activators, wherein Dl-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

IPC Classes  ?

• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 33/32 - ManganeseCompounds thereof
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention disclosed herein relates to novel synergistic medicinal compositions for treating dysfunctional D-serine (DSR) signaling. Particularly the invention provides potent synergistic medicinal composition comprising combination of N-acetyl taurinate salt of divalent metal (M2+AT) as serine racemase enzyme (SR) activator/stimulator and benzoic acid ester salt of monovalent or divalent metals (M+/2+Bz) as d-amino acid oxidase enzyme (DAAO) inhibitor, which are present in weight ratio of 1:0.001 to 1:1.5 along with pharmaceutically acceptable excipients. Further the present synergistic medicinal composition is useful for treating certain neuropsychiatric disorders, neurological disorders and metabolic disorders.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The present invention relates to compositions for enhancing TFEB-mediated intracellular clearance. Particularly, the invention relates to complex comprising synergistic combination of polyamine and histidine-containing dipeptide present in a specific weight ratio along with pharmaceutically acceptable excipients. More particularly, the invention relates to composition comprising synergistic blend of N-(3-Aminopropyl)-l,4-butanediamine and N-a-Acetyl-N-p-alanyl-L-histidine and salts thereof along with pharmaceutically acceptable excipients. Furthermore, the present synergistic composition is useful for improving or inducing autophagy, lysosomal biogenesis, mitophagy and lipophagy.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form